Maravai LifeSciences/$MRVI
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Maravai LifeSciences
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
- Ticker
- $MRVI
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 415
- Headquarters
- San Diego, United States
- Website
- www.maravai.com
MRVI Metrics
BasicAdvanced
$1.2B
-
-$0.53
0.58
-
Price and volume
Market cap
$1.2B
Beta
0.58
52-week high
$9.42
52-week low
$2.55
Average daily volume
2.4M
Financial strength
Current ratio
4.052
Quick ratio
2.635
Long term debt to equity
0.583
Total debt to equity
0.854
Interest coverage (TTM)
-2.86%
Profitability
EBITDA (TTM)
-19.745
Gross margin (TTM)
35.71%
Net profit margin (TTM)
-37.07%
Operating margin (TTM)
-32.82%
Effective tax rate (TTM)
0.30%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-5.71%
Return on equity (TTM)
-33.05%
Valuation
Price to revenue (TTM)
5.464
Price to book
5.68
Price to tangible book (TTM)
-18.33
Price to free cash flow (TTM)
-31.825
Free cash flow yield (TTM)
-3.14%
Free cash flow per share (TTM)
-0.245
Growth
Revenue change (TTM)
-5.03%
Earnings per share change (TTM)
-60.70%
3-year revenue growth (CAGR)
-27.33%
3-year earnings per share growth (CAGR)
-2.59%
What the Analysts think about MRVI
Analyst ratings (Buy, Hold, Sell) for Maravai LifeSciences stock.
Analyst projections of the future price of Maravai LifeSciences stock.
Bulls say / Bears say
Second-quarter 2026 revenue rose 9% year on year, with TriLink up 11.5% and Cygnus up 2.8% for its fifth consecutive quarter of growth. Maravai also raised its full-year adjusted EBITDA guidance to $33 million–$35 million, signalling improving operating leverage. (Maravai LifeSciences)
Demand is building in higher-value RNA products: GMP consumables grew 55% and Discovery mRNA grew 17% year on year in Q2, while ModTail had attracted more than 125 customers. The new GMP enzyme facility has also shipped its first commercial batch, supporting Maravai’s effort to serve customers from research through production. (The Motley Fool, Maravai LifeSciences)
The June refinancing cut borrowings roughly in half and pushed the term-loan maturity to 2032. With $70.1 million of cash at quarter-end, this eases near-term refinancing pressure and gives the business more time to execute its recovery. (The Motley Fool)
Maravai recorded $14.3 million of high-volume CleanCap sales for commercial COVID vaccine programmes in Q1, but said it does not expect further high-volume orders from those programmes in 2026. That creates a tough comparison and leaves the business exposed to episodic demand. (SEC)
Maravai kept its 2026 revenue outlook unchanged after Q2, noting that large GMP orders and CDMO projects depend on customer schedules. This makes near-term sales less predictable, even as management expects growth in TriLink. (The Motley Fool)
The company still reported a $21.6 million net loss in Q2 despite positive adjusted EBITDA. The improvement has yet to translate into GAAP profitability, so the turnaround remains incomplete. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 13 Oct 2026.
MRVI Financial Performance
Revenues and expenses
MRVI Earnings Performance
Company profitability
Upcoming events
No upcoming events
MRVI News
AllArticlesVideos
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
Business Wire2 weeks ago
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
Business Wire1 month ago
Maravai LifeSciences Q2 Earnings Call Highlights
MarketBeat3 months ago
Funds containing MRVI
Fund name | Fund size | $MRVI weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.10% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.10% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.08% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.